What is Immix Biopharma, Inc.'s investment proceeds?

Immix Biopharma, Inc. (IMMX) reported investment proceeds of $3M in Q1 2026.

What does investment proceeds mean?

Cash received from sales, maturities, and redemptions of investment securities across all categories.

Immix Biopharma, Inc. IMMX Investment Proceeds

Investment Proceeds at other companies

Allogene TherapeuticsALLO

$72.12M+27.6%

XencorXNCR

$99.97M-16.0%

ImmunomeIMNM

$0-100%

PrecigenPGEN

$55.1M+1,105%

Iovance Biotherapeutics, Inc.IOVA

$74M-38.3%

Artiva Biotherapeutics, Inc.ARTV

$22M-24.1%

Other financials

Income statement

See full

Operating income-$10.8M-131%

Net income-$10.1M-122%

EPS (diluted)-$0.18-20.0%

Balance sheet

See full

Cash & equivalents$79.3M+398%

Total debt$1.0M-2.0%

Total equity$84.4M+779%

Total assets$95.8M+382%

Cash flow

See full

Operating cash flow-$9.8M-483%

CapEx$32.5K-52.0%

Free cash flow-$9.9M-462%

Valuation

See full

Market cap$691.97M+1,008%

Enterprise value$613.75M+1,190%

Returns & leverage

See full

Return on equity-74.4%-18.6pp

Debt / equity0×-0.1×

Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immix Biopharma, Inc.'s investment proceeds?: Immix Biopharma, Inc. (IMMX) reported investment proceeds of $3M in Q1 2026.
What does investment proceeds mean?: Cash received from sales, maturities, and redemptions of investment securities across all categories.